Salta al contenuto principale
Ricerc@Sapienza
Toggle navigation
Home
Login
Home
Persone
paolo.marchetti@uniroma1.it
Paolo Marchetti
Professore Ordinario
Struttura:
DIPARTIMENTO DI MEDICINA CLINICA E MOLECOLARE
E-mail:
paolo.marchetti@uniroma1.it
Pagina istituzionale corsi di laurea
Curriculum Sapienza
Pubblicazioni
Titolo
Pubblicato in
Anno
Adjuvant vemurafenib in resected, BRAF V600 mutation-positive melanoma (BRIM8): a randomised, double-blind, placebo-controlled, multicentre, phase 3 trial
THE LANCET ONCOLOGY
2018
Observational study of coagulation activation in early breast cancer. development of a prognostic model based on data from the real world setting
JOURNAL OF TRANSLATIONAL MEDICINE
2018
Body mass index in HER2-negative metastatic breast cancer treated with first-line paclitaxel and bevacizumab
CANCER BIOLOGY & THERAPY
2018
Systemic chemotherapy for advanced rare pancreatic histotype tumors: A retrospective multicenter analysis
PANCREAS
2018
Sarcopenia is associated with reduced survival in patients with advanced hepatocellular carcinoma undergoing sorafenib treatment
UNITED EUROPEAN GASTROENTEROLOGY JOURNAL
2018
Non-invasive visualization of tumor infiltrating lymphocytes in patients with metastatic melanoma undergoing immune checkpoint inhibitor therapy. A pilot study
ONCOTARGET
2018
Resolution of remitting seronegative symmetrical synovitis with pitting edema (RS3PE) during Nivolumab therapy for non-small cell lung cancer: a case report
SEMINARS IN ARTHRITIS AND RHEUMATISM
2018
Evaluation of 5-fluorouracil degradation rate and pharmacogenetic profiling to predict toxicity following adjuvant capecitabine
EUROPEAN JOURNAL OF CLINICAL PHARMACOLOGY
2017
Cross-talk between microbiota and immune fitness to steer and control response to anti PD-1/PDL-1 treatment
ONCOTARGET
2017
Angiosarcoma of the breast: a rare and dismal complication of breast surgery associated with radiation
THE AMERICAN SURGEON
2017
Tackling pancreatic cancer with metronomic chemotherapy
CANCER LETTERS
2017
Pharmacogenetic Approach to Toxicity in Breast Cancer Patients Treated with Taxanes
ANTICANCER RESEARCH
2017
A nomogram to predict 5-fluorouracil toxicity: when pharmacogenomics meets the patient
ANTI-CANCER DRUGS
2017
Current achievements and future perspectives of metronomic chemotherapy
INVESTIGATIONAL NEW DRUGS
2017
Patient database analysis of fulvestrant 500 mg in the treatment of metastatic breast cancer: A European perspective
THE BREAST
2017
A retrospective multicentric observational study of trastuzumab emtansine in HER2 positive metastatic breast cancer: a real-world experience
ONCOTARGET
2017
Fasting glucose and body mass index as predictors of activity in breast cancer patients treated with everolimus-exemestane: the EverExt study
SCIENTIFIC REPORTS
2017
PD-L1 expression in TNBC: a predictive biomarker of response to neoadjuvant chemotherapy?
BIOMED RESEARCH INTERNATIONAL
2017
The role of stereotactic body radiation therapy in oligometastatic colorectal cancer
MEDICINE
2017
Safety and tolerability of subcutaneous trastuzumab for the adjuvant treatment of human epidermal growth factor receptor 2-positive early breast cancer: SafeHer phase III study's primary analysis of 2573 patients
EUROPEAN JOURNAL OF CANCER
2017
« prima
< precedente
…
2
3
4
5
6
7
8
9
10
11
12
13
seguente ›
ultima »
© Università degli Studi di Roma "La Sapienza" - Piazzale Aldo Moro 5, 00185 Roma